CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, ...

A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Here are five medical breakthroughs that gave us hope in 2025. In February, a baby with a rare, often fatal genetic disorder ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

Explore 2025's groundbreaking scientific discoveries: the MoM-z14 galaxy, personalised CRISPR therapy, regenerative medicine, ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD" has been ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made another round of trades on Christmas Eve, December 24, sticking ...

From smartphones to artificial intelligence, technology moved from the margins of daily life to its center, transforming how ...

USA Today names the Philadelphia Mummers Parade the country’s best holiday parade. Heading into its 125th year, the slightly ...

A longtime university president reflects on her hometown of Philadelphia's blessings in higher education and medical ...

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...